118 related articles for article (PubMed ID: 23207289)
21. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer.
Trovik J; Wik E; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; Njolstad TS; ; Vandenput I; Amant F; Akslen LA; Salvesen HB
Clin Cancer Res; 2011 May; 17(10):3368-77. PubMed ID: 21242118
[TBL] [Abstract][Full Text] [Related]
22. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma.
Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S
Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241
[TBL] [Abstract][Full Text] [Related]
23. Fluorescence in situ hybridization and immunohistochemical analysis of p53 expression in endometrial cancer: prognostic value and relation to ploidy.
Graesslin O; Chantot-Bastaraud S; Lorenzato M; Birembaut P; Quéreux C; Daraï E
Ann Surg Oncol; 2008 Feb; 15(2):484-92. PubMed ID: 18071824
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
25. The association between p53 expression, stage and histological features in endometrial cancer.
Ragni N; Ferrero S; Prefumo F; Muschiato B; Gorlero F; Gualco M; Fulcheri E
Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):111-6. PubMed ID: 15894417
[TBL] [Abstract][Full Text] [Related]
26. Cyclooxygenase-2 and p53 expressions in endometrial cancer.
Jeon YT; Kang S; Kang DH; Yoo KY; Park IA; Bang YJ; Kim JW; Park NH; Kang SB; Lee HP; Song YS
Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1538-42. PubMed ID: 15342458
[TBL] [Abstract][Full Text] [Related]
27. Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients.
Garzetti GG; Ciavattini A; Goteri G; De Nictolis M; Romanini C
Gynecol Oncol; 1996 Apr; 61(1):16-21. PubMed ID: 8626110
[TBL] [Abstract][Full Text] [Related]
28. Evolution in endometrial cancer: evidence from an immunohistochemical study.
Vandenput I; Trovik J; Leunen K; Wik E; Stefansson I; Akslen L; Moerman P; Vergote I; Salvesen H; Amant F
Int J Gynecol Cancer; 2011 Feb; 21(2):316-22. PubMed ID: 21734474
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor.
Zhao C; Bratthauer GL; Barner R; Vang R
Am J Surg Pathol; 2007 Sep; 31(9):1378-86. PubMed ID: 17721194
[TBL] [Abstract][Full Text] [Related]
31. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
32. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.
Acs G; Pasha T; Zhang PJ
Int J Gynecol Pathol; 2004 Apr; 23(2):110-8. PubMed ID: 15084838
[TBL] [Abstract][Full Text] [Related]
33. Clinical factors affecting the diagnostic accuracy of assessing dilation and curettage vs frozen section specimens for histologic grade and depth of myometrial invasion in endometrial carcinoma.
Wang X; Zhang H; Di W; Li W
Am J Obstet Gynecol; 2009 Aug; 201(2):194.e1-194.e10. PubMed ID: 19564019
[TBL] [Abstract][Full Text] [Related]
34. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
35. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer.
Hylander B; Repasky E; Shrikant P; Intengan M; Beck A; Driscoll D; Singhal P; Lele S; Odunsi K
Gynecol Oncol; 2006 Apr; 101(1):12-7. PubMed ID: 16263157
[TBL] [Abstract][Full Text] [Related]
36. Comparison between adenocarcinoma in both endocervical and endometrial specimens from fractional curettage and pathologic findings in subsequent hysterectomy specimens.
Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S
J Med Assoc Thai; 2008 Sep; 91(9):1313-7. PubMed ID: 18843857
[TBL] [Abstract][Full Text] [Related]
37. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
38. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
Roberts DJ; Haber D; Sklar J; Crum CP
Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
[TBL] [Abstract][Full Text] [Related]
39. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
Moritani S; Ichihara S; Hasegawa M; Endo T; Oiwa M; Yoshikawa K; Sato Y; Aoyama H; Hayashi T; Kushima R
Hum Pathol; 2008 May; 39(5):666-71. PubMed ID: 18339419
[TBL] [Abstract][Full Text] [Related]
40. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]